Moran Eye Center Physician Helps Inform New FDA Warnings on GLP-1 Drugs and Eye Strokes
Nov 18, 2026
Patient cases flagged by a physician-scientist at the John A. Moran Eye Center were among those helping to inform a new FDA warning about potential vision complications associated with popular diabetes and weight-loss medications.
On November 9, the FDA announced it is requiring new warnings for widely used so-called GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, after finding a higher occurrence rate of a rare condition that can cause sudden, permanent vision loss among patients taking the medications.
The action comes nearly two years after Moran neuro-ophthalmologist Bradley J. Katz, MD, PhD, and colleagues published an investigatory review in JAMA Ophthalmology documenting the condition, non-arteritic anterior ischemic optic neuropathy (NAION), sometimes called an eye stroke, among patients taking the popular medications.
The FDA reviewed clinical trials, observational studies, and reports of adverse events. Its analysis of 126 randomized clinical trials involving more than 134,000 patients found a higher rate of NAION. Although rare, NAION can cause sudden, painless, and potentially permanent vision loss, often in one eye.
“In 2025 we published about nine patients to highlight an association in patients taking these medications," Katz said. "The FDA has now taken steps to make sure doctors and patients are aware of this association, but more research is needed to really determine whether it is a causal one. We don't know whether GLP-1s themselves cause higher rates or whether it's really the diseases GLP-1s are treating, like diabetes."
In the JAMA article, Katz and colleagues discussed nine patients who experienced vision complications while taking semaglutide or tirzepatide, medications commonly prescribed for type 2 diabetes and obesity. Seven patients developed NAION. Two others experienced different complications affecting the optic nerve or retina.
What should patients on GLP-1 drugs or thinking about starting them do now? Katz said:
People taking GLP-1 medications should not discontinue treatment solely because of the new warning without consulting your prescribing doctor.
Anyone who experiences sudden vision loss should seek immediate medical evaluation.
Diabetics should continue their regular eye examinations, and those who have previously experienced NAION should discuss the potential risks with their doctor.
“These medications can have important health benefits, and we don't want patients to be unnecessarily alarmed,” Katz said. “The risk of this type of vision loss appears to be very low. The important thing is to get medical attention right away if you notice sudden changes in your vision and talk with your doctor about any concerns.”
Read the FDA's November 2026 Safety Communication
Watch an Interview with Dr. Katz on LiveNOW from FOX
vision
clinical care
neuro-ophthalmology